You are here

Class Action Lawsuit Claims Mylan Acted With PBMs to Inflate EpiPen Price

Company sued under federal law usually reserved for organized crime

A new proposed class action lawsuit filed in Tacoma, Washington, claims that Mylan engaged in a scheme with pharmacy benefit managers (PBMs) to dominate the epinephrine auto-injector market and overcharge consumers for its EpiPen, according to a Reuters report. The cost of the allergy treatment ballooned to more than $600 for a two-pack of the device from less than $100 in 2007.

Although Mylan has been slapped with other EpiPen-related lawsuits, this is the first one to focus on the role of PBMs and to bring claims under the Racketeer Influenced and Corrupt Organizations Act, a federal law historically used against organized crime. The suit was filed by three EpiPen purchasers.

When asked about the suit by Reuters, a Mylan spokesperson declined to comment.

The plaintiffs say Mylan paid large rebates to PBMs so they would favor the EpiPen over competitors. In helping Mylan control 95% of the epinephrine auto-injector market, the rebates artificially inflated the EpiPen’s sticker price, resulting in higher costs for many patients, the suit said.

The lawsuit also claims that the three largest PBMs in the U.S.––CVS Caremark, part of CVS Health; Express Scripts Holding Co.; and OptumRX, part of UnitedHealth Group Inc.––participated in Mylan’s alleged scheme. They were not named as defendants.

The plaintiffs are seeking damages to represent a nationwide class of EpiPen purchasers.

Source: Reuters; April 3, 2017.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs